Protease inhibitors and anticonvulsants.

J. Brooks, Johanna P. Daily, L. Schwamm

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Due to adverse interactions, manufacturers of four licensed protease inhibitors are recommending that their products not be used with the three most frequently prescribed anticonvulsants: carbamazepine, phenobarbitol, and phenytoin. These adverse interactions and their causes are discussed, suggesting that concomitant administration of protease inhibitors may induce early viral resistance and possibly accelerate HIV progression. Further, ritonavir and nelfinavir use may raise serum levels of these anticonvulsants into toxic ranges. Although not approved for single-agent use in the United States, two anticonvulsants that are theoretically less prone to interact adversely with protease inhibitors are gabapentin and lamotrigine. Protocols to manage patients on protease inhibitors and anticonvulsants are suggested.

Original languageEnglish (US)
JournalAIDS clinical care
Volume9
Issue number11
StatePublished - 1997
Externally publishedYes

Fingerprint

Protease Inhibitors
Anticonvulsants
Nelfinavir
Ritonavir
Poisons
Carbamazepine
Phenytoin
HIV
Serum

Cite this

Protease inhibitors and anticonvulsants. / Brooks, J.; Daily, Johanna P.; Schwamm, L.

In: AIDS clinical care, Vol. 9, No. 11, 1997.

Research output: Contribution to journalArticle

Brooks, J, Daily, JP & Schwamm, L 1997, 'Protease inhibitors and anticonvulsants.', AIDS clinical care, vol. 9, no. 11.
Brooks, J. ; Daily, Johanna P. ; Schwamm, L. / Protease inhibitors and anticonvulsants. In: AIDS clinical care. 1997 ; Vol. 9, No. 11.
@article{6d3d4d2f88af4a4090723c244ac2d2c2,
title = "Protease inhibitors and anticonvulsants.",
abstract = "Due to adverse interactions, manufacturers of four licensed protease inhibitors are recommending that their products not be used with the three most frequently prescribed anticonvulsants: carbamazepine, phenobarbitol, and phenytoin. These adverse interactions and their causes are discussed, suggesting that concomitant administration of protease inhibitors may induce early viral resistance and possibly accelerate HIV progression. Further, ritonavir and nelfinavir use may raise serum levels of these anticonvulsants into toxic ranges. Although not approved for single-agent use in the United States, two anticonvulsants that are theoretically less prone to interact adversely with protease inhibitors are gabapentin and lamotrigine. Protocols to manage patients on protease inhibitors and anticonvulsants are suggested.",
author = "J. Brooks and Daily, {Johanna P.} and L. Schwamm",
year = "1997",
language = "English (US)",
volume = "9",
journal = "AIDS clinical care",
issn = "1043-1543",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - Protease inhibitors and anticonvulsants.

AU - Brooks, J.

AU - Daily, Johanna P.

AU - Schwamm, L.

PY - 1997

Y1 - 1997

N2 - Due to adverse interactions, manufacturers of four licensed protease inhibitors are recommending that their products not be used with the three most frequently prescribed anticonvulsants: carbamazepine, phenobarbitol, and phenytoin. These adverse interactions and their causes are discussed, suggesting that concomitant administration of protease inhibitors may induce early viral resistance and possibly accelerate HIV progression. Further, ritonavir and nelfinavir use may raise serum levels of these anticonvulsants into toxic ranges. Although not approved for single-agent use in the United States, two anticonvulsants that are theoretically less prone to interact adversely with protease inhibitors are gabapentin and lamotrigine. Protocols to manage patients on protease inhibitors and anticonvulsants are suggested.

AB - Due to adverse interactions, manufacturers of four licensed protease inhibitors are recommending that their products not be used with the three most frequently prescribed anticonvulsants: carbamazepine, phenobarbitol, and phenytoin. These adverse interactions and their causes are discussed, suggesting that concomitant administration of protease inhibitors may induce early viral resistance and possibly accelerate HIV progression. Further, ritonavir and nelfinavir use may raise serum levels of these anticonvulsants into toxic ranges. Although not approved for single-agent use in the United States, two anticonvulsants that are theoretically less prone to interact adversely with protease inhibitors are gabapentin and lamotrigine. Protocols to manage patients on protease inhibitors and anticonvulsants are suggested.

UR - http://www.scopus.com/inward/record.url?scp=0031263335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031263335&partnerID=8YFLogxK

M3 - Article

VL - 9

JO - AIDS clinical care

JF - AIDS clinical care

SN - 1043-1543

IS - 11

ER -